Antibody-drug conjugates (ADCs) are emerging as a promising therapeutic approach for advanced endometrial cancer. These innovative treatments combine targeted antibodies with cytotoxic drugs to selectively attack cancer cells while minimizing damage to healthy tissues. Recent clinical trials have demonstrated encouraging results for several ADCs in this setting.
One notable investigational ADC is rinatabart sesutecan (Rina-S), which targets folate receptor alpha (FRα) expressed on many endometrial cancer cells. In a Phase I/II study, Rina-S exhibited a confirmed objective response rate of 55.6% in patients with advanced ovarian cancer, suggesting potential efficacy in endometrial cancer as well. Click for More Details
